EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GV-971 Ameliorates Chronic Restraint Stress-Induced Depression-like Phenotypes Accompanied by Reshaping of the Microbiota–Gut–Brain Axis

Zhuandi He, Yali Nie iD, Changcai Li, Guangqiang Sun, Wei Zheng, Hongchun Liu iD, Meiyu Geng, Jingwei Tian, Yu Zhang

Marine Drugs · 24.05.2026 · 24 (6) · 189

DOI: 10.3390/md24060189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Marine Drugs, online erschienen am 24.05.2026. Verfasst von Zhuandi He und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation…. Hauptthemen laut MEDLINE: Depression, Gastrointestinal Microbiome, Stress, Psychological, Brain-Gut Axis. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R&D Program of Shandong Province, China, Shandong Provincial Natural Science Foundation, Shandong Laboratory Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Depression is increasingly linked to microbiota–gut–brain axis dysfunction, yet current monoaminergic antidepressants show limited efficacy. This study investigated the therapeutic potential and underlying mechanisms of GV-971, a marine-derived oligosaccharide, in a chronic restraint stress (CRS) mouse model. We first established that 8 h of daily restraint for 4–8 weeks induces a stable depression-like phenotype characterized by behavioral despair and significant reduction in peripheral monoamine neurotransmitters (5-HT and norepinephrine). GV-971 treatment robustly attenuated CRS-induced depression- and anxiety-like behaviors, restored hippocampal serotonin levels, reduced elevated plasma corticosterone concentrations, and ameliorated CRS-induced adrenal cortical hyperplasia. Mechanistically, GV-971 significantly suppressed neuroinflammation by inhibiting microglial hyperactivation in the prefrontal cortex and hippocampus. Concurrently, it repaired intestinal barrier dysfunction, evidenced by reduced permeability, restored mucosal integrity, and recovered goblet cell numbers. Crucially, integrated shot-gun metagenomics and plasma metabolomics revealed that GV-971 not only reshaped microbial taxonomy but also functionally recalibrated the gut ecosystem. It enriched beneficial taxa (e.g., Bifidobacterium pseudolongum, Bacteroides uniformis) and specific metabolic pathways, leading to increased short-chain fatty acids (valeric and caproic acids) and a significant reduction in plasma levels of tryptophan–kynurenine pathway metabolites, specifically the neurotoxic compounds kynurenine and quinolinic acid. Fecal microbiota transplantation (FMT) from GV-971-treated donors partially recapitulated the antidepressant and gut-protective effects in CRS recipients, confirming a causal role for the remodeled microbiota. Collectively, GV-971 exerts antidepressant effects by coordinately remodeling the gut microbiota, normalizing tryptophan and SCFA metabolism, restoring gut barrier integrity, and dampening central neuroinflammation, supporting its potential as a novel gut–brain axis-targeted therapy for depression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DepressionGastrointestinal MicrobiomeStress, PsychologicalBrain-Gut AxisOligosaccharidesAntidepressive AgentsAnimalsMaleMiceRestraint, PhysicalDisease Models, AnimalMice, Inbred C57BLBrainPhenotypeHippocampusIntestinal Barrier Function

Stichwörter der Autor:innen

GV-971depressionfecal microbiota transplantationmicrobiota–gut–brain axisneuroinflammationtryptophan metabolism

Substanzen

OligosaccharidesAntidepressive Agents

Autor:innen und Institutionen

  • School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universi…
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

ORCID-Profile: Yali Nie, Hongchun Liu

Förderung

  • Key R&D Program of Shandong Province, China
  • Shandong Provincial Natural Science Foundation
  • Shandong Laboratory Program

Zitieren

APA

He, Z., Nie, Y., Li, C., Sun, G., Zheng, W., Liu, H., Geng, M., Tian, J., & Zhang, Y. (2026). GV-971 Ameliorates Chronic Restraint Stress-Induced Depression-like Phenotypes Accompanied by Reshaping of the Microbiota–Gut–Brain Axis. Marine Drugs, 24(6), 189. https://doi.org/10.3390/md24060189

Vancouver

He Z, Nie Y, Li C, Sun G, Zheng W, Liu H, et al. GV-971 Ameliorates Chronic Restraint Stress-Induced Depression-like Phenotypes Accompanied by Reshaping of the Microbiota–Gut–Brain Axis. Marine Drugs. 2026;24(6):189. doi:10.3390/md24060189

BibTeX
@article{He2026,
  author = {He, Zhuandi and Nie, Yali and Li, Changcai and Sun, Guangqiang and Zheng, Wei and Liu, Hongchun and Geng, Meiyu and Tian, Jingwei and Zhang, Yu},
  title = {GV-971 Ameliorates Chronic Restraint Stress-Induced Depression-like Phenotypes Accompanied by Reshaping of the Microbiota–Gut–Brain Axis},
  journal = {Marine Drugs},
  year = {2026},
  volume = {24},
  number = {6},
  pages = {189},
  doi = {10.3390/md24060189}
}
Kostenlos starten →